share_log

热景生物(688068.SH):参股公司研制的创新药SGC001注射液临床试验申请获批准许可

Beijing Hotgen Biotech Co., Ltd. (688068.SH): Clinical trial application for innovative drug SGC001 injection developed by affiliated company has been approved for permission.

Gelonghui Finance ·  Aug 5 03:36

Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced that its affiliated company, Beijing ShunJing Biomedical Technology Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) with the notice number 2024LP01790. The clinical trial application (IND) for innovative drug SGC001 injection developed by ShunJing medical has been approved by the NMPA. SGC001 is an emergency monoclonal antibody drug jointly developed by Professor Sun Zhiwei's research team of ShunJing medical and Professor Du Jie's team of Beijing Institute of Heart, Lung and Blood Vessel Diseases of Capital Medical University. It is applicable to the emergency treatment of patients with Acute Myocardial Infarction (AMI) (the first indication is Anterior wall ST segment elevation myocardial infarction).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment